Search results for "Schedule"

showing 10 items of 567 documents

The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen.

2010

OBJECTIVES: To determine the efficacy and safety of different opioids used in doses proportional to the basal opioid regimen for the management of breakthrough pain (BP). METHODS: In 66 patients consecutive patients admitted to a pain relief and palliative care unit, the efficacy and safety of different opioids used in doses proportional to the basal opioid regimen for the management of breakthrough pain (BP) were assessed. The choice of the opioid to be administered as rescue medication was based on the characteristics of patients, clinical stability, compliance, preference, and so on. For each episode, nurses were instructed to routinely collect changes in pain intensity and emerging prob…

MalePalliative careBreakthrough PainAdministration OralPainDrug Administration ScheduleSex FactorsClinical ProtocolsMedicinebreakthrough pain; acute palliative care unit; opioidsHumansAgedPain MeasurementAnalgesicsDose-Response Relationship Drugbusiness.industryPalliative CareAge FactorsopioidsMiddle Agedacute palliative care unitbreakthrough painClinical trialAnalgesics OpioidRegimenAnesthesiology and Pain MedicineNociceptionTreatment OutcomeBasal (medicine)OpioidAnesthesiaFemaleNeurology (clinical)businessCancer painmedicine.drug
researchProduct

Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose

2003

Breakthrough pain is normally severe in intensity and has a rapid onset. The availability of supplemental doses of opioids (rescue medication) in addition to the continuous analgesic medication is the main treatment suggested to manage these pain flares. The intravenous (i.v.) route may provide analgesia fast enough, but has never been assessed in clinical studies. The aim of this open-label study was to verify the safety and effectiveness of an i.v. dose equal to one-fifth the calculated equianalgesic total daily dose in advanced cancer patients with episodic pain. A consecutive sample of 48 cancer patients treated with oral morphine, who reported an acceptable basal analgesia and reported…

MalePalliative careExacerbationSafety and effectiveness of intravenous morphineAnalgesicPainDrug Administration ScheduleOral administrationNeoplasmsmorphine doseMedicineHumansAdverse effectGeneral NursingDose-Response Relationship DrugMorphineepisodic (breakthrough) painbusiness.industryPalliative CareMiddle AgedEquianalgesicAnalgesics OpioidAnesthesiology and Pain MedicineAnesthesiaInjections IntravenousMorphineFemaleNeurology (clinical)businessCancer painmedicine.drug
researchProduct

Lymphocytic Mitochondrial Aconitase Activity is Reduced in Alzheimer's Disease and Mild Cognitive Impairment

2015

Background: Specific mechanisms behind the role of oxidative/nitrosative stress and mitochondrial dysfunction in Alzheimer's disease (AD) pathogenesis remain elusive. Mitochondrial aconitase (ACO2) is a Krebs cycle enzyme sensitive to free radicalmediated damage. Objective: We assessed activity and expression of ACO2 extracted from blood lymphocytes of subjects with AD, mild cognitive impairment (MCI), older adults with normal cognition (OCN, age >= 65 years), and younger adults with normal cognition (YCN, age < 65 years). Plasma levels and activities of antioxidants were also measured. Methods: Blood samples were collected from 28 subjects with AD, 22 with MCI, 21 OCN, and 19 YCN. ACO2 act…

MalePathologyantioxidantAntioxidantmedicine.medical_treatmentLymphocyteMitochondrionmedicine.disease_causePolymerase Chain ReactionPathogenesisVitamin Eoxidative stressLymphocytesaconitase (aconitate hydratase)Aconitate Hydratasereactive oxygen speciesGeneral NeuroscienceACO2General MedicineAlzheimer's diseasemitochondriaPsychiatry and Mental healthClinical Psychologyantioxidantsmedicine.anatomical_structureDisease ProgressionSettore MED/26 - NeurologiaFemaleAlzheimer diseaseAlzheimer's diseaseAzheimer diseasereactive nitrogen speciemedicine.medical_specialtyaconitase (aconitate hydratase); Alzheimer disease; antioxidants; free radicals; lymphocyte; mild cognitive impairment; mitochondria; oxidative stress; reactive nitrogen species; reactive oxygen speciesBlotting Westernfree radicalslymphocytemild cognitive impairmentInternal medicinemedicineHumansCognitive DysfunctionRNA MessengerAgedfree radicaloxidative strebusiness.industryVitamin EAconitasimedicine.diseasereactive nitrogen speciesEndocrinologyGeriatrics and GerontologyAlzheimer's disease; Aconitasi; oxidative stress; Aconitase (aconitate hydratase) Azheimer disease antioxidants free radicals lymphocyte mild cognitive impairment mitochondria oxidative stress reactive nitrogen species reactive oxygen speciesMental Status SchedulebusinessBiomarkersOxidative stressJournal of Alzheimer's Disease
researchProduct

Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease

2013

Abstract New diagnostic criteria for Alzheimer's disease (AD) treat different biomarkers of neuronal injury as equivalent. Here, we quantified the degree of agreement between hippocampal volume on structural magnetic resonance imaging, regional glucose metabolism on positron emission tomography, and levels of phosphorylated tau in cerebrospinal fluid (CSF) in 585 subjects from all phases of the AD Neuroimaging Initiative. The overall chance-corrected agreement was poor (Cohen κ, 0.24–0.34), in accord with a high rate of conflicting findings (26%–41%). Neither diagnosis nor APOE e4 status significantly influenced the distribution of agreement between the biomarkers. The degree of agreement t…

MalePathologymedicine.medical_specialtyEpidemiologytau ProteinsHippocampus03 medical and health sciencesCellular and Molecular NeuroscienceApolipoproteins E0302 clinical medicineAtrophyCerebrospinal fluidDevelopmental NeuroscienceNeuroimagingAlzheimer DiseaseFluorodeoxyglucose F18medicineHumansDementiaCognitive DysfunctionAged030304 developmental biology0303 health sciencesChi-Square Distributionmedicine.diagnostic_testHealth PolicyMiddle Agedmedicine.diseasePsychiatry and Mental healthPositron emission tomographyPositron-Emission TomographyBiomarker (medicine)FemaleNeurology (clinical)AtrophyGeriatrics and GerontologyAlzheimer's diseaseMental Status SchedulePsychologyChi-squared distributionBiomarkers030217 neurology & neurosurgeryAlzheimer's &amp; Dementia
researchProduct

Strategies and actions of multi-purpose health communication on vaccine preventable infectious diseases in order to increase vaccination coverage in …

2017

The ESCULAPIO Project aims at increasing awareness on vaccine preventable infectious diseases (VPID) and vaccinations in different target populations and to spread the culture of prevention. Information/training interventions on VPID have been developed and health promotion activities for the general population, students and their parents, teachers and health care workers (HCWs) were set up. In Tuscany, educational courses on VPID in high schools were organized and students were stimulated to prepare informative materials on VPID for lower grade school pupils. In Liguria, an educational card game (named 'Vaccine at the Fair') was presented to children of primary schools. Stands in shopping …

MalePediatricsVaccination schedulePsychological interventionSettore MED/42 - Igiene Generale E Applicataawareness; communication; general population; health care workers; infectious diseases; students; vaccination coverage; vaccineinfectious diseasesgeneral population0302 clinical medicinevaccineHealth careImmunology and Allergyawareness030212 general & internal medicineeducation.field_of_studyVaccinesvaccination coverageSchoolsstudentscommunicationVaccinationResearch PapersVaccinationItalyOrder (business)Femalemedicine.medical_specialtystudentAdolescentinfectious disease030231 tropical medicineImmunologyPopulationeducationawarenehealth care workers03 medical and health sciencesYoung AdultmedicineDisease Transmission InfectiousHumanseducationHealth communicationPharmacologybusiness.industryHealth promotionHealth Communicationhealth care workerFamily medicinebusinessHuman vaccinesimmunotherapeutics
researchProduct

Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-co…

2005

Objective The safety of a booster dose of a reduced-antigen-content tetanus–diphtheria–acellular pertussis (Tdap) vaccine was evaluated in adolescents previously vaccinated with five doses of acellular pertussis–containing vaccine. Study design Adolescents (n = 319) previously vaccinated with either 5 doses of diphtheria–tetanus–acellular pertussis (DTaP) (n = 193) or 4 doses of DTaP plus another acellular pertussis–containing vaccine received one dose each of Tdap and hepatitis A vaccine in a double-blinded, randomized, crossover trial. Rates of adverse events (AEs) after vaccination with Tdap versus hepatitis A and rates of local AEs among adolescents vaccinated with Tdap (sixth acellular…

MalePediatricsmedicine.medical_specialtyAdolescentWhooping CoughHepatitis A vaccineBooster doseDiphtheria-Tetanus-acellular Pertussis Vaccinescomplex mixturesSeverity of Illness IndexDouble-Blind MethodGermanymedicineHumansProspective StudiesAdverse effectChildWhooping coughImmunization ScheduleAntigens BacterialCross-Over StudiesTetanusDose-Response Relationship Drugbusiness.industryTetanusDiphtheriaIncidenceVaccinationHepatitis ADiphtheriamedicine.diseaseSurgeryVaccinationTreatment OutcomePediatrics Perinatology and Child HealthFemalebusinessFollow-Up StudiesThe Journal of pediatrics
researchProduct

Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according t…

2012

CONTEXT: In the absence of an effective vaccine, serogroup B Neisseria meningitidis (MenB) remains a major cause of invasive disease in early childhood in developed countries. OBJECTIVE: To determine the immunogenicity and reactogenicity of a multicomponent MenB vaccine (4CMenB) and routine infant vaccines when given either concomitantly or separately. DESIGN, SETTING, AND PARTICIPANTS: Phase 2b, multicenter, open-label, parallel-group, randomized controlled study of 1885 infants enrolled at age 2 months from August 2008 to July 2010 in Europe. INTERVENTION: Participants were randomized 2:2:1:1 to receive (1) 4CMenB at 2, 4, and 6 months with routine vaccines (7-valent pneumococcal and comb…

MalePediatricsmedicine.medical_specialtyContext (language use)Meningococcal VaccinesMeningococcal vaccineNeisseria meningitidisSerum Bactericidal Antibody AssayDrug Administration SchedulemedicineHumansImmunization ScheduleVaccinesVaccines SyntheticReactogenicityTetanusbusiness.industryDiphtheriaInfantGeneral Medicinemedicine.diseasePoliomyelitisVaccinationMeningococcal InfectionsAntibody FormationFemalePertactinbusiness
researchProduct

The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-…

2003

To evaluate immune responses, safety and reactogenicity of the concomitant use of DTaP-IPV-Hib and the newly available 7-valent pneumococcal conjugate (7VPnC) vaccines when given as the primary immunization series in early infancy. A total of 231 healthy infants were enrolled at 11 German study centers and randomized to receive either 7VPnC plus DTaP-IPV-Hib vaccines concomitantly into opposite limbs at age 2, 3, 4 and 11-15 months (7VPnC group) or DTaP-IPV-Hib vaccine at the same ages plus a 7VPnC "catch-up vaccination" at ages 6, 7, 8 and 11-15 months (Control group). Blood samples were drawn before and 4 weeks after the first three vaccine doses and 4 weeks after the fourth dose. Local a…

MalePediatricsmedicine.medical_specialtyImmunization SecondaryEnzyme-Linked Immunosorbent AssayHerpesvirus VaccinesAntibodies ViralPneumococcal conjugate vaccinePneumococcal VaccinesmedicineHumansVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesHerpesvirus 1 BovineReactogenicityVaccines ConjugateGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryDiphtheriaImmunogenicityPublic Health Environmental and Occupational HealthInfantmedicine.diseaseAntibodies BacterialVaccinationPoliovirus VaccinesInfectious DiseasesImmunizationConcomitantChild PreschoolImmunologyMolecular MedicineFemalePertactinbusinessmedicine.drugVaccine
researchProduct

Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity diso…

2019

The present study investigated whether symptom reduction in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) treated with guanfacine extended release (GXR) can be explained by sedative effects of the medication. Data from four double-blind, randomized, placebo-controlled, phase 3 trials of GXR monotherapy (1-7 mg/day; morning administration) in children (aged 6-12 years) and adolescents (aged 13-17 years) with ADHD were analyzed post hoc. Two studies used forced-dose titration and two used flexible-dose titration. Efficacy was determined using ADHD Rating Scale IV (ADHD-RS-IV) scores. Sedative treatment-emergent adverse events (TEAEs) included somnolence, sedati…

MalePediatricsmedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classSedationDrug Administration Schedule03 medical and health sciences0302 clinical medicineDouble-Blind MethodRating scalemedicineHumansHypnotics and SedativesAttention deficit hyperactivity disorderPharmacology (medical)ChildAdverse effectBiological PsychiatryMorningPsychiatric Status Rating ScalesPharmacologyDose-Response Relationship Drugbusiness.industrymedicine.diseaseGuanfacine030227 psychiatryGuanfacinePsychiatry and Mental healthTreatment OutcomeNeurologyAttention Deficit Disorder with HyperactivityDelayed-Action PreparationsSedativeFemaleNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgerySomnolenceFollow-Up Studiesmedicine.drugEuropean Neuropsychopharmacology
researchProduct

Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study

2003

Abstract Background. Rabeprazole is a new proton pump inhibitor, which has been reported to induce a faster acid suppression than other drugs of the same category. This might be useful to reduce the duration of anti-Helicobacter therapies. Aims. The aim of this study was to assess whether there is the possibility of shortening a rabeprazole-based triple therapy from 7 to 4 days without compromising its efficacy in the eradication of Helicobacter pylori infection. Patients. A total of 128 consecutive dyspeptic patients with H. pylori infection were recruited for this controlled, randomized, open and parallel-group trial comparing the efficacy of two durations of the same rabeprazole-based tr…

MalePeptic Ulcermedicine.medical_specialtymedicine.drug_classUrea breath testRabeprazoleProton-pump inhibitorPilot ProjectsGastroenterology2-PyridinylmethylsulfinylbenzimidazolesDrug Administration ScheduleHelicobacter InfectionsAnti-Infective AgentsClarithromycinMetronidazoleClarithromycinInternal medicinemedicineHumansProspective StudiesDyspepsiaAdverse effectHelicobacter pyloriHepatologybiologymedicine.diagnostic_testbusiness.industryGastroenterologyProton Pump InhibitorsMiddle AgedHelicobacter pyloriAnti-Ulcer Agentsbiology.organism_classificationAnti-Bacterial AgentsMetronidazoleRegimenTreatment OutcomeRabeprazoleBenzimidazolesDrug Therapy CombinationFemalebusinessOmeprazolemedicine.drug
researchProduct